INCA033989 clinical trials

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

This study looks at a new drug, INCA033989, alone or with ruxolitinib, for blood cancers called myeloproliferative neoplasms. Researchers want to find a safe and effective dose, checking for side effects and how well patients can tolerate the treatment.